Fundraising FoxMPM BioImpact — 2020 Investments
5 investments dated 2020 · listed companies and verified rows first · show all
Dyne Therapeutics develops targeted therapies for genetically driven neuromuscular diseases using its proprietary FORCE platform.
BiotechMedical DevicesWaltham, US
Romesh Subramanian, Ph.D.(Executive Officer)Richard Scalzo(Executive Officer)Joshua Brumm(Executive Officer, Director)Jonathan McNeill, M.D.(Executive Officer)inOxana Beskrovnaya, Ph.D.(Executive Officer)John G. Cox(President and Chief Executive Officer)in
Co-investorsAtlas VentureHercules Capital, Inc.Vida VenturesWellington ManagementForbionRA Capital
Werewolf Therapeutics is a biotechnology company developing immunotherapy treatments for cancer.
BiotechHealthtechMedical DevicesWatertown, US
Daniel J. Hicklin(Founder, President, Chief Executive Officer, and Board member)Luke Evnin(Co-founder, Board member (Chairman))inDavid Cordo(Executive Officer)Alon Lazarus(Director)
BoardChristoph Westphal(Director)
Board seatLuke EvninBriggs Morrison· per SEC Form D
Co-investorsDC Investment PartnersK2 HealthVenturesLongwood FundRA CapitalTaiho Ventures, LLCUPMC Enterprises
Orna Therapeutics develops RNA and lipid nanoparticle (LNP) based therapies for treating diseases including oncology and cell therapy applications.
AI & Machine LearningBiotechMedical Devices
Joe Bolen(Chief Executive Officer)Joe Bolen, Ph.D.(Chief Executive Officer)Hope D'Oyley-Gay, JD(Chief Legal Officer)Ciaran Lawlor, Ph.D.(Chief Operating Officer)Frank Neumann, M.D., Ph.D.(Chief Medical Officer)Siva Sakhamuri(Chief Technology Officer)in
Co-investorsAstellas Venture Management LLCTaiho Ventures, LLC
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.